New combo tackles tough liver cancer in tiny trial
NCT ID NCT06354387
First seen Mar 30, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This small pilot study tested a combination of two drugs, alectinib and nivolumab, in 5 adults with advanced liver cancer that had not responded to standard treatments. The goal was to see if the combination could shrink tumors. Because it was a very early phase 1 trial with very few participants, the results are preliminary and not enough to draw firm conclusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CMUH
Taichung, Taiwan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Alectinib (Alecensa) and Nivolumab (Opdivo)
What this could lead to
If it works, this could point toward a new combination treatment for advanced liver cancer patients who have run out of options.
What could go wrong
This is a very early, tiny pilot study with only 5 participants, so results may not apply to others. The combination may cause side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.